NBIX
Neurocrine Biosciences, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +12.8% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 5 | -1 | 774.42K | $108.76M | n/a | −1 |
| Q2 2026 | 154 | 0 | 76.05M | $12.81B | +5 | −4 |
| Q1 2026 | 156 | 0 | 77.10M | $10.14B | +6 | −7 |
| Q4 2025 | 155 | 0 | 77.25M | $10.95B | +1 | n/a |
| Q3 2025 | 22 | 0 | 59.57M | $8.36B | +1 | −2 |
| Q2 2025 | 20 | -1 | 49.44M | $6.21B | +2 | −3 |
| Q1 2025 | 18 | 0 | 22.97M | $2.54B | +1 | −1 |
| Q4 2024 | 18 | 0 | 21.48M | $2.93B | +1 | −1 |
| Q3 2024 | 17 | 0 | 13.43M | $1.55B | n/a | n/a |
| Q2 2024 | 17 | n/a | 11.91M | $1.64B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Renaissance Technologies ✦ | 2.57M | +4.3% | $296.64M | 0.4% | ▲ Add | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 1.86M | +2.2% | $213.77M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 3 | AQR Capital Management ✦ | 1.84M | +50.7% | $212.20M | 0.3% | ▲ Add | 2 | SEC ↗ ×5 |
| 4 | Citadel Advisors ✦ | 1.76M | +138.2% | $203.32M | 0.2% | ▲ Add | 2 | SEC ↗ ×2 |
| 5 | T. Rowe Price ✦ | 1.68M | -6.9% | $193.01M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 6 | Dodge & Cox ✦ | 1.29M | +0.6% | $148.38M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 7 | Wellington Management ✦ | 718.23K | -20.1% | $82.75M | 0.0% | ▼ Trim | 2 | SEC ↗ ×7 |
| 8 | PRIMECAP Management ✦ | 404.00K | -1.3% | $46.55M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 9 | Norges Bank ✦ (passive) | 351.06K | -21.9% | $40.45M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 10 | Millennium Management ✦ | 312.77K | +66.8% | $36.04M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | D. E. Shaw & Co. ✦ | 169.45K | +56.4% | $19.52M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 12 | Soros Fund Management ✦ | 150.00K | -23.0% | $17.28M | 0.5% | ▼ Trim | 2 | SEC ↗ |
| 13 | Bridgewater Associates ✦ | 135.19K | +54.4% | $15.58M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 14 | Two Sigma Investments ✦ | 90.03K | -33.5% | $10.37M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 15 | Fisher Asset Management ✦ | 68.27K | +7.8% | $7.87M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 16 | Gotham Asset Management ✦ | 15.32K | -60.0% | $1.76M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 17 | Arrowstreet Capital ✦ | 8.65K | +148.4% | $996,768 | 0.0% | ▲ Add | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 690 holders, 94.09M shares, $12.08B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 826 sh · $130,051
Officer · 2.31K sh · $363,285
Officer · 2.15K sh · $333,030
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology